Rui Su, PhD

Beckman Research Institute of the City of Hope

Titles + affiliations

Assistant Professor, Department of Systems Biology
Beckman Research Institute of the City of Hope


The Role of TET2 in Modulating Leukemia Stem Cell Homing and Reprogramming Immune Response


Acute myeloid leukemia (AML) is one of the most common blood cancers in the United States with over 20,050 new cases and 11,540 deaths estimated in 2022. Despite the considerable advances, the five-year survival rate of AML patients is still lower than 30%. Ten Eleven Translocation 2 (TET2) is recurrently deleted and/or mutated in 15-20% AML patients and TET2 deficiency leads to poorer prognosis and drug resistance. Therefore, it’s unmet medical to develop novel efficient approach to cure AMLs, especially the patients with TET2 mutation. Very recently, we have discovered that TET2 deficiency facilitates the homing of leukemia stem cells (LSCs) into the bone marrow (BM) niche to support their self-renewal and initiate leukemogenesis. LSCs is responsible for AML relapse and chemotherapy, and eliminating LSCs has been recognized as the “holy grail” of anti-leukemia treatment. Moreover, we also identified that loss of TET2 leads to the immune evasion of AML cells from CD8+ T cell surveillance in leukemia microenvironment. In this proposal, my lab aims to systemically delineate the role of TET2 in LSC homing and leukemia immunity and reveal the underlying molecular mechanism(s). We believe that the better understanding of TET2 in AML BM microenvironment will substantially contribute to the development of more specific and efficient therapies against the very aggressive AMLs with TET2 deficiency.


Leukemia Research Foundation grant
$100K awarded in 2022

Disease focus
Acute myeloid leukemia (AML)

Research focus
Cancer cell biology (leukemia stem cells)